Neglected Tropical Disease Treatment Market Report and Forecast 2025-2034

The global neglected tropical disease treatment market was valued at USD 3.92 Billion in 2024, driven by the increasing initiatives to raise awareness about neglected tropical diseases and access to medicines by the governments across the globe. The market is anticipated to grow at a CAGR of 4.80% during the forecast period of 2025-2034 to achieve a value of USD 6.26 Billion by 2034.

Neglected Tropical Disease Treatment Market Overview

Neglected tropical diseases (NTDs) are treated through a combination of medications, vaccines, and supportive care tailored to the specific disease. Treatments include anti-parasitic drugs, antibiotics, antifungals, and emerging biologics to combat infections caused by bacteria, parasites, and viruses. Vaccines play a preventive role, especially for diseases like dengue and rabies. Supportive measures, including wound care and nutritional supplementation, are essential for recovery and improving patient outcomes. Innovative therapies and combination treatments are increasingly employed to enhance efficacy and minimise drug resistance. Expanding access to treatments in underserved areas remains a priority to reduce the global burden of NTDs.

Neglected Tropical Disease Treatment Market Growth Drivers

Expansion of Global Partnerships Driving Market Growth

Growing investment in research and development and increasing advocacy for neglected tropical diseases (NTDs) are driving the global market forward. For instance, In December 2024, the Global Health Innovative Technology (GHIT) Fund and the World Health Organization (WHO) signed a memorandum of understanding (MoU) to enhance their collaboration in addressing NTDs. Their focus includes advancing research for new treatments and interventions, mobilising resources through an NTD investment toolkit, and raising awareness globally and locally. This strategic partnership is poised to accelerate access to affordable and effective solutions for NTDs. The expanded cooperation will stimulate market growth by improving global health frameworks and encouraging innovation in NTD treatments and vaccines, creating significant market momentum in the forecast period.

Indigenous Vaccine Development Paving Path for Neglected Tropical Disease Treatment Market Value in Developing Countries

Rising government investments and the growing demand for regional solutions are key drivers of the NTD market. For instance, in August 2024, India’s Council of Medical Research (ICMR) and Panacea Biotec launched the first-ever Phase 3 clinical trial for the country’s indigenous tetravalent dengue vaccine. This vaccine, developed to combat all four dengue virus serotypes, is crucial in a country where dengue remains a significant public health challenge. With successful Phase 1 and 2 trials, this initiative is set to transform the market by introducing a locally developed solution. The anticipated approval and availability of this vaccine will catalyse market growth, making the NTD space more robust, with increased attention to vaccine development during the forecast period.

Neglected Tropical Disease Treatment Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Increased Funding Driving Growth in the Market

A non-profit charitable organization Christian Blind Mission (CBM) mentioned significant investments and initiatives across seven countries in its annual report for 2024, directly contributing to the market's growth. With over 88 million doses of preventive chemotherapy administered in 2023, these efforts underscore the expanding global commitment to tackling NTDs. Moreover, CBM's support for advanced trachoma surgeries and training initiatives signifies the growing emphasis on sustainable healthcare solutions. The focus on water, sanitation, and hygiene (WASH) further strengthens preventive measures, driving demand for solutions across multiple sectors. In the forecast period, these continuous efforts are poised to accelerate the NTD market's development and value globally.

Global Progress in Treatments to Enhances Neglected Tropical Diseases Treatment Market Value

According to the WHO's January 2023 report, the global fight against NTDs has witnessed considerable strides, especially with countries eliminating key diseases. With 47 countries eliminating at least one NTD by 2022 and 80 million fewer people requiring interventions, this progress will lead to enhanced market development. The focus on water safety, sanitation, and healthcare access in the report reveals an increased demand for comprehensive treatment and prevention strategies. As countries continue to make advancements, the market is expected to experience sustained growth, further driven by increasing global healthcare investments and collaboration to tackle neglected tropical diseases in endemic regions.

Technological Advancements to Augment Neglected Tropical Diseases Treatment Market Size

Technological innovations, including rapid diagnostic tests and digital health platforms, are reshaping the neglected tropical diseases market. Improved diagnostic tools enable faster and more accurate detection, particularly in remote and underserved areas. Digital health solutions facilitate data collection, monitoring, and targeted interventions, optimising disease management. These advancements enhance the value of healthcare delivery by reducing treatment delays and costs. In the forecast period, the integration of emerging technologies is poised to expand market opportunities, ensuring better accessibility and improved outcomes for affected populations.

Growing Awareness and Funding to Meet Rising Neglected Tropical Diseases Treatment Market Demand

Increased awareness campaigns and funding initiatives for neglected tropical diseases are driving market opportunities globally. Advocacy by international organisations and local governments has heightened public understanding of these diseases, encouraging early detection and treatment. Enhanced funding from global health entities supports R&D, leading to the development of innovative therapies and broader distribution networks. This growing awareness and financial backing are expected to significantly impact market dynamics, fostering equitable healthcare access and contributing to the reduction of disease burdens in endemic regions during the forecast period.

Neglected Tropical Disease Treatment Market Segmentation

Neglected Tropical Disease Treatment Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:

Market Breakup by Disease Type

• Dengue
• Rabies
• Trachoma
• Buruli Ulcer
• Yaws
• Leprosy
• Chagas Disease
• Mediterranean Fever
• Human African Trypanosomiasis (Sleeping Sickness)
• Leishmaniases
• Soil-transmitted Helminthiases
• Others

Market Breakup by Treatment

• Drugs
• Anti-Parasite
• Antifungal
• Antibiotics
• Others
• Vaccines

Market Breakup by Route of Administration

• Oral
• Parenteral

Market Breakup by End User

• Hospital
• Specialty Clinics
• Homecare Settings
• Others

Market Breakup by Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Neglected Tropical Disease Treatment Market Share

Dengue to Dominate the Segment by Disease Type

Dengue is likely to hold the largest share of the market by disease type, driven by its widespread prevalence and increasing incidence rates, especially in tropical and subtropical regions. As per the analysis by Expert Market Research, the global dengue testing market is likely to grow at a CAGR of 4.6% by 2034. The disease’s significant health burden has led to heightened governmental initiatives, research funding, and vaccine development. Additionally, the rising awareness and availability of effective treatment options are accelerating its diagnosis and management. In the forecast period, continued advancements in diagnostic tools, alongside the rollout of novel vaccines, are expected to strengthen dengue's position as the leading segment, driving overall market growth and improving healthcare access globally.

Segment by Treatment to Hold Significant Neglected Tropical Disease Treatment Market Value

Drugs are poised to represent the largest segment in the market by treatment due to their widespread use in combating neglected tropical diseases. Anti-parasitic, antifungal, and antibiotic therapies are crucial for addressing diverse disease types. Rising investments in drug discovery and the development of novel formulations enhance their accessibility and efficacy. The availability of cost-effective generic options further supports their adoption, particularly in low- and middle-income countries. With a growing focus on expanding healthcare infrastructure and improving treatment coverage, the drug segment is set to sustain its dominance and contribute significantly to market expansion during the forecast period.

Neglected Tropical Disease Treatment Market Segmentation by Route of Administration to Witness Growth

Oral administration is likely to dominate the market by route of administration due to its convenience, patient compliance, and cost-effectiveness. This segment benefits from the extensive availability of oral drug formulations, which are easy to distribute and administer, especially in resource-limited settings. Rising innovation in oral drug delivery systems, such as extended-release tablets and combination therapies, further enhances treatment outcomes. In the forecast period, the increasing emphasis on improving access to healthcare in remote regions is expected to reinforce the leadership of oral administration, boosting market growth and ensuring more effective management of neglected tropical diseases.

Hospitals to Lead the Segmentation by End User

Hospitals are expected to hold the largest neglected tropical disease treatment market share by end-user, owing to their comprehensive diagnostic and treatment capabilities. They provide access to advanced technologies, expert medical staff, and specialised care, making them the preferred choice for managing complex cases of neglected tropical diseases. Growing government investments in public health infrastructure and the rising number of patients seeking hospital care are significant drivers for this segment. During the forecast period, hospitals are anticipated to maintain their dominance, supported by ongoing developments in healthcare systems and increased focus on early disease detection and effective treatment protocols.

Hospital Pharmacy to Dominate the Neglected Tropical Disease Treatment Market by Distribution Channel

Hospital pharmacies will likely dominate the market by distribution channel, primarily due to their direct access to patients and the availability of a wide range of essential medications. They play a critical role in ensuring timely and accurate dispensing of drugs, particularly in urgent and severe cases of neglected tropical diseases. The growing integration of electronic prescribing and inventory systems in hospital pharmacies enhances efficiency and accessibility. In the forecast period, hospital pharmacies are expected to retain their leading position, driven by advancements in healthcare delivery models and their pivotal role in supporting comprehensive patient care.

Neglected Tropical Disease Treatment Market Analysis by Region

Asia Pacific is expected to hold the largest market share driven by a high disease burden, particularly in densely populated and low-income regions. Countries like India, Indonesia, and the Philippines report significant cases of diseases such as dengue, leprosy, and soil-transmitted helminthiases. Substantial government initiatives, international aid, and increased healthcare spending enhance access to treatments and diagnostics. Meanwhile, North America and Europe benefit from advanced R&D and funding for neglected disease treatments, although their case numbers are comparatively lower. Latin America, with diseases like Chagas and leishmaniasis, and the Middle East and Africa, heavily affected by sleeping sickness and rabies, also contribute to market growth through regional collaborations and awareness campaigns.

Leading Players in the Neglected Tropical Disease Treatment Market

The key features of the market report comprise patent analysis, clinical trials analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Pfizer Inc

Headquartered in New York, USA, and established in 1849, Pfizer Inc. is a leading global biopharmaceutical company. Its portfolio in the neglected tropical diseases market includes treatments for parasitic infections and antibiotic therapies. The company is committed to addressing global health challenges, focusing on improving access to medicines in underserved regions. Through partnerships and philanthropic programmes, Pfizer enhances healthcare delivery for diseases such as trachoma and soil-transmitted helminthiases, contributing significantly to efforts aimed at reducing the global burden of neglected tropical diseases.

F. Hoffmann-La Roche

Founded in 1896 and headquartered in Basel, Switzerland, F. Hoffmann-La Roche is a global leader in pharmaceuticals and diagnostics. The company’s portfolio in neglected tropical diseases includes innovative diagnostics and therapies targeting parasitic and bacterial infections. Roche leverages its expertise in molecular diagnostics to support early and accurate detection of diseases such as Chagas and leishmaniasis. Committed to advancing public health, Roche collaborates with global organisations to enhance access to its solutions in regions heavily impacted by neglected tropical diseases, aligning with its mission to improve lives worldwide.

Bayer AG

Bayer AG, established in 1863 and headquartered in Leverkusen, Germany, is a multinational life sciences company focusing on healthcare and agriculture. In the neglected tropical diseases market, Bayer offers treatments for diseases such as Chagas and African sleeping sickness, with a strong emphasis on anti-parasitic therapies. The company actively collaborates with global health organisations and supports donation programmes to improve access to essential medicines in low-resource settings. Bayer’s commitment to tackling neglected diseases underscores its broader mission to enhance global health and promote sustainable development.

Takeda Pharmaceutical Company Limited

Headquartered in Tokyo, Japan, Takeda Pharmaceutical Company Limited is a global leader in healthcare, focusing on innovative treatments for various diseases, including neglected tropical diseases (NTDs). The company’s commitment to addressing global health challenges is evident through strategic partnerships, such as its collaboration with Biological E. Limited in February 2024 . This partnership aims to accelerate the availability of QDENGA® (Dengue Tetravalent Vaccine) to endemic countries by 2030, with an annual production capacity of up to 100 million doses. Takeda's involvement in NTDs extends to other therapeutic areas, positioning it as a key player in the global fight against tropical diseases.

Other key players in the market include Sanofi, Merck & Co., Inc., GSK Plc, Johnson and Johnson Services Inc., Gilead Sciences, Inc., and Novartis.

Key Questions Answered in the Neglected Tropical Disease Treatment Market

• What was the global neglected tropical disease treatment market value in 2024?
• What is the neglected tropical disease treatment market forecast outlook for 2025-2034?
• What is market segmentation based on disease type?
• What is market segmentation based on treatment?
• How is the market segmented based on the route of administration?
• How is the market segmented based on distribution channels?
• What is market segmentation based on end users?
• What are the major factors aiding the neglected tropical disease treatment market demand?
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major neglected tropical disease treatment market trends?
• Which disease type will lead the market segment?
• Which treatment will lead the market segment?
• Which route of administration will lead the market segment?
• Which end user will lead the market segment?
• Which distribution channel will lead the market segment?
• Who are the key players involved in the neglected tropical disease treatment market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

This product will be delivered within 3-5 business days.